Leading Executives in Other Chemicals and Pharmaceuticals
Albert Bourla
Chairman and Chief Executive Officer, Pfizer
Pfizer’s Chairman and CEO who led the company’s rapid development and global rollout of its COVID-19 vaccine and is now steering a post‑pandemic reset and oncology push.
Joaquin Duato
Chairman and Chief Executive Officer, Johnson & Johnson
Veteran operator who became CEO in January 2022 and Chair in January 2023, leading J&J’s focus on Innovative Medicine and MedTech after the Kenvue separation.
Robert M. Davis
Chairman and Chief Executive Officer, Merck & Co. (MSD)
Former CFO and president who became CEO on July 1, 2021 and Chair on December 1, 2022, guiding Merck’s growth in oncology and vaccines.
David A. Ricks
Chair and Chief Executive Officer, Eli Lilly and Company
Chair and CEO since 2017 credited with record R&D output and business performance as Lilly scales breakthroughs in diabetes, obesity and neuroscience.
Robert A. Michael
Chairman of the Board and Chief Executive Officer, AbbVie
Long‑time AbbVie leader who became CEO in 2024 and was named Chairman in February 2025; helped steer the Humira LOE transition and diversification strategy.
Robert A. Bradway
Chairman and Chief Executive Officer, Amgen
Veteran dealmaker and operator leading Amgen since 2012 (CEO) and 2013 (Chair), with deep experience from finance to operations.
Daniel O’Day
Chairman and Chief Executive Officer, Gilead Sciences
Ex‑Roche Pharma chief who became Gilead’s Chair and CEO in 2019; active industry voice as current chair of PhRMA.
Christopher (Chris) Boerner, PhD
Board Chair and Chief Executive Officer, Bristol Myers Squibb
Commercial strategist turned operator who became CEO in November 2023 and Board Chair in April 2024, after roles as CCO and COO.
Vasant (Vas) Narasimhan, MD
Chief Executive Officer, Novartis
Physician‑CEO since 2018 leading Novartis’ transformation into a focused medicines company and advancing platform technologies like radioligand and gene/cell therapies.
Thomas Schinecker, PhD
Chief Executive Officer, Roche Group
Diagnostics veteran who became Group CEO in 2023, emphasizing pipeline execution while maintaining a diversified pharma and diagnostics engine.
Paul Hudson
Chief Executive Officer, Sanofi
CEO since 2019 driving a modernization agenda and R&D refocus while embedding sustainability and culture at the core of strategy.
Pascal Soriot
Chief Executive Officer, AstraZeneca
CEO since 2012 credited with rebuilding the pipeline and setting bold 2030 growth ambitions; has signaled no plans to retire.
Jim Fitterling
Chair and Chief Executive Officer, Dow
Chair and CEO who led Dow’s transformation toward higher‑growth materials science and is recognized for industry‑leading sustainability and inclusion leadership (2024 Palladium Medal).
Lori D. Koch
Chief Executive Officer, DuPont
Finance leader turned CEO in June 2024, now executing DuPont’s portfolio simplification and planned three‑way separation to unlock value.
Dr. Markus Kamieth
Chairman of the Board of Executive Directors (CEO), BASF
Organic chemist who became CEO in April 2024; now steering the portfolio and BASF’s Net Zero Accelerator priorities.
Peter Vanacker
Chief Executive Officer, LyondellBasell
Former Neste chief appointed to drive circularity and sustainability at one of the world’s largest plastics and chemicals companies; active leader at the ACC and ICCA.
Ilham Kadri, PhD
Chief Executive Officer, Syensqo
Orchestrated Solvay’s 2023 demerger and now leads Syensqo, the advanced‑materials company, with a growth agenda grounded in sustainability.
Philippe Kehren
Chief Executive Officer, Solvay
Led Solvay’s essential‑chemicals business and now CEO post spin‑off; focused on cost discipline and energy transition in soda ash and derivatives.
Christian Kullmann
Chairman of the Executive Board (CEO), Evonik Industries
CEO since 2017 driving Evonik’s shift to specialty chemicals; now executing the company’s largest restructuring to boost growth and efficiency.
Related Topics
Further Reading
Was this page helpful? We'd love your feedback — please email us at feedback@dealstream.com.